Assessing the impact of emergency medicine pharmacists on fibrinolytic door-to-needle times in acute ischemic stroke: A systematic review and meta-analysis (Pharmacist-assisted Stroke Treatments I (PhAST-1))
Abstract
Background: Acute ischemic stroke (AIS) requires time-sensitive fibrinolytic therapy measured by door-to-needle (DTN) time. Emergency medicine pharmacists (EMPs) are integral in emergency departments (EDs) for optimizing AIS care as they possess expertise in drug therapy and emergency response.
Objective: The purpose of this systematic review and meta-analysis (SR/MA) is to evaluate EMP impact on DTN time.
Methods: This SR/MA searched multiple databases. Eligibility criteria included adult ED patients with AIS receiving fibrinolytics with defined EMP involvement. The primary endpoint was fibrinolytic DTN time. Secondary endpoints included achievement of timely fibrinolytic and length of stay (LOS). Meta-analysis was conducted using random-effects models.
Results: Of 494 total citations identified, 214 citations met screening criteria with 22 studies undergoing full text review and 9 observational, retrospective, cohort studies included. A total of 1064 patients were included for MA with 441 (41.4 %) in the EMP present group and 623 (58.6 %) in the EMP absent group. EMP presence was associated with reduced mean DTN time by 14.6 min (95 % CI -18.1, -11.1 min). Odds of achieving a DTN within 60- and 45-min was higher with EMP presence, OR 2.85 (95 % CI 1.40, 5.79) and 2.75 (95 % CI 1.99, 3.79), respectively. ICU LOS was longer by 2.07 days in the EMP present group, but hospital LOS was not different between groups.
Conclusions: EMP presence during AIS management is associated…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 1,064 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.